Skip to main content

COMBATIENDO LAS BACTERIAS RESISTENTES A LOS ANTIBIOTICOS Y CONTROLANDO SU EVOLUCION IN VIVO MEDIANTE ESTRATEGIAS INNOVADORAS Y NUEVOS TESTS DE DIAGNOSTICO CLINICO

PID2019-105512RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Singlet oxygen and radical-mediated mechanisms in the oxidative cellular damage photosensitized by the protease inhibitor simeprevir

  • García-Laínez, Guillermo
  • El Ouardi, Meryem
  • Moreno, Alejandro
  • Lence, Emilio
  • González-Bello, Concepción
  • Miranda, Miguel Á.
  • Andreu, Inmaculada|||0000-0003-3409-9443
[EN] Hepatitis C, a liver inflammation caused by the hepatitis C virus (HCV), is treated with antiviral drugs. In this context, simeprevir (SIM) is an NS3/4A protease inhibitor used in HCV genotypes 1 and 4. It is orally admin-istered and achieves high virological cure rates. Among adverse reactions associated with SIM treatment, photosensitivity reactions have been reported. In the present work, it is clearly shown that SIM is markedly phototoxic, according to the in vitro NRU assay using BALB/c 3T3 mouse fibroblast. This result sheds light on the nature of the photosensitivity reactions induced by SIM in HCV patients, suggesting that porphyrin elevation in patients treated with SIM may not be the only mechanism responsible for SIM-associated photosensitivity. Moreover, lipid photoperoxidation and protein photooxidation assays, using human skin fibroblasts (FSK) and human serum albumin (HSA), respectively, reveal the capability of this drug to promote photodamage to cellular membranes. Also, DNA photo lesions induced by SIM are noticed through comet assay in FSK cells. Photo-chemical and photobiological studies on the mechanism of SIM-mediated photodamage to biomolecules indicate that the key transient species generated upon SIM irradiation is the triplet excited state. This species is efficiently quenched by oxygen giving rise to singlet oxygen, which is responsible for the oxidation of lipids and DNA (Type II mechanism). In the presence of HSA, the photobehavior is dominated by binding to site 3 of the protein, to give a stable SIM@HSA complex. Inside the complex, quenching of the triplet excited state is less efficient, which results in a longer triplet lifetime and in a decreased singlet oxygen formation. Hence, SIM-mediated photoox-idation of the protein is better explained through a radical (Type I) mechanism., Financial support from the Spanish Ministry of Science and Innovation [PID2020-115010RB-I00/AEI/10.13039/501100011033 (I.A), PID2019-105512RB-I00/AEI/10.13039/501100011033 (CG-B) and FPU predoctoral fellowship for M. El O.], Axencia Galega de Innovacion (2020-PG067, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigacion de Galicia accreditation 2019-2022 (ED431G 2019/03),], and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputacion de Galicia (CESGA) for use of the Finis Terrae computer.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Switching from ultrafast electron transfer to proton transfer in excited drug-protein complexes upon biotransformation

  • Tamarit-Mayo, Lorena
  • Andreu, Inmaculada|||0000-0003-3409-9443
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • El Ouardi, Meryem
  • Lence, Emilio
  • González-Bello, Concepción
  • Miranda Alonso, Miguel Ángel
[EN] Photosensitization by drugs is directly related with the excited species and the photoinduced processes arising from interaction with UVA light. In this context, the ability of gefitinib (GFT), a tyrosine kinase inhibitor (TKI) used for the treatment of a variety of cancers, to induce phototoxicity and photooxidation of proteins has recently been demonstrated. In principle, photodamage can be generated not only by a given drug but also by its photoactive metabolites that maintain the relevant chromophore. In the present work, a complete study of O-desmorpholinopropyl gefitinib (GFT-MB) has been performed by means of fluorescence and ultrafast transient absorption spectroscopies, in addition to molecular dynamics (MD) simulations. The photobehavior of the GFT-MB metabolite in solution is similar to that of GFT. However, when the drug or its metabolite are in a constrained environment, i.e. within a protein, their behavior and the photoinduced processes that arise from their interaction with UVA light are completely different. For GFT in complex with human serum albumin (HSA), locally excited (LE) singlet states are mainly formed; these species undergo photoinduced electron transfer with Tyr and Trp. By contrast, since GFT-MB is a phenol, excited state proton transfer (ESPT) to form phenolate-like excited species might become an alternative deactivation pathway. As a matter of fact, the protein-bound metabolite exhibits higher fluorescence yields and longer emission wavelengths and lifetimes than GFT@HSA. Ultrafast transient absorption measurements support direct ESPT deprotonation of LE states (rather than ICT), to form phenolate-like species. This is explained by MD simulations, which reveal a close interaction between the phenolic OH group of GFT-MB and Val116 within site 3 (subdomain IB) of HSA. The reported findings are relevant to understand the photosensitizing properties of TKIs and the role of biotransformation in this type of adverse side effects., Financial support from the Spanish Ministry of Science and Innovation (RYC-2015-17737, BEAGAL 18/00211, PID2020-115010RB-I00/AEI/10.13039/501100011033, FPU19/00048, PID2019-105512RB-I00/AEI/10.13039/501100011033), the Xunta de Galicia (ED431C 2021/29), the Centro singular de investigacion de Galicia accreditation 2019-2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputacion de Galicia (CESGA) for use of the Finis Terrae computer.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Bicyclic Boronate β-Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens

  • Lence Quintana, Emilio José
  • González Bello, Concepción
The use of β-lactamase inhibitors in combination with β-lactam antibiotics is an emerging area in drug discovery. This strategy allows the restoration of the therapeutic efficacy of these antibiotics in clinical use against multiresistant bacteria. These pathogens are drug resistant because they express β-lactamase enzymes, which prevent the antibiotic therapeutic action by catalyzing the hydrolysis of the β-lactam ring. These enzymes are quite diverse in both their structural architecture and hydrolytic capability, as well as in the mechanism of action. The ever-increasing emergence of pathogens that are capable of coproducing different types of β-lactamases has triggered the search for ultrabroad-spectrum inhibitors capable of deactivating both serine- and metallo-β-lactamases. A recent breakthrough in this long-pursued and unmet need is the discovery of bicyclic boronate inhibitors, specifically taniborbactam, VNRX-7145, and QPX7728, which are currently under clinical development in combination with cefepime, ceftibuten, and QPX2014, respectively. The present article highlights the therapeutic potential of these inhibitors and their spectrum of efficacy is compared with those of other β-lactam/β-lactamase inhibitor combinations recently approved by the food and drug administration. The molecular basis of the ultrabroad-spectrum of activity of boron-based inhibitors is also discussed, on the basis of the available crystal structures and the results of computational studies
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Crambescin C1 acts as a possible substrate of iNOS and eNOS increasing nitric oxide production and inducing in vivo hypotensive effect

  • Rubiolo Gaytán, Juan Andrés
  • Lence Quintana, Emilio José
  • González Bello, Concepción
  • Roel Fernández, María
  • Gil Longo, José
  • Campos Toimil, Manuel
  • Ternon, Eva
  • Thomas, Olivier P.
  • González Cantalapiedra, Antonio
  • López Alonso, Henar
  • Rodríguez Vieytes, Mercedes
  • Botana López, Luis Miguel
Crambescins are guanidine alkaloids from the sponge Crambe crambe. Crambescin C1 (CC) induces metallothionein genes and nitric oxide (NO) is one of the triggers. We studied and compared the in vitro, in vivo, and in silico effects of some crambescine A and C analogs. HepG2 gene expression was analyzed using microarrays. Vasodilation was studied in rat aortic rings. In vivo hypotensive effect was directly measured in anesthetized rats. The targets of crambescines were studied in silico. CC and homo-crambescine C1 (HCC), but not crambescine A1 (CA), induced metallothioneins transcripts. CC increased NO production in HepG2 cells. In isolated rat aortic rings, CC and HCC induced an endothelium-dependent relaxation related to eNOS activation and an endothelium-independent relaxation related to iNOS activation, hence both compounds increase NO and reduce vascular tone. In silico analysis also points to eNOS and iNOS as targets of Crambescin C1 and source of NO increment. CC effect is mediated through crambescin binding to the active site of eNOS and iNOS. CC docking studies in iNOS and eNOS active site revealed hydrogen bonding of the hydroxylated chain with residues Glu377 and Glu361, involved in the substrate recognition, and explains its higher binding affinity than CA. The later interaction and the extra polar contacts with its pyrimidine moiety, absent in the endogenous substrate, explain its role as exogenous substrate of NOSs and NO production. Our results suggest that CC serve as a basis to develop new useful drugs when bioavailability of NO is perturbed
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Discovery of 3H-pyrrolo[2,3-c]quinolines with activity against Mycobacterium tuberculosis by allosteric inhibition of the glutamate-5-kinase enzyme

  • Panciera, Michele
  • Lence Quintana, Emilio José
  • Rodríguez-Costa, Ángela
  • Gracia Díaz, Begoña
  • Aínsa Claver, José Antonio
  • Marco-Marin, Clara
  • Rubio, Vicente
  • Correia, Carlos Roque Duarte
  • González Bello, Concepción
The therapeutic potential of 3H-pyrrolo[2,3-c]quinolines—the main core of Marinoquinoline natural products—has been explored for the development of new anti-TB agents. The chemical modification of various positions in this scaffold has led to the discovery of two pyrroloquinolines (compounds 50 and 54) with good in vitro activity against virulent strains of Mycobacterium tuberculosis (H37Rv, MIC = 4.1 μM and 4.2 μM, respectively). Enzymatic assays showed that both derivatives are inhibitors of glutamate-5-kinase (G5K, encoded by proB gene), an essential enzyme for this pathogen involved in the first step of the proline biosynthesis pathway. G5K catalyzes the phosphoryl-transference of the γ-phosphate group of ATP to L-glutamate to provide L-glutamyl-5-phosphate and ADP, and also regulates the synthesis of L-proline. The results of various molecular dynamics simulation studies revealed that the inhibition of G5K would be caused by allosteric interaction of these compounds with the interface between enzyme domains, against different pockets and with distinct recognition patterns. The binding of compound 54 promotes long-distance conformational changes at the L-glutamate binding site that would prevent it from anchoring for catalysis, while compound 50 alters the ATP binding site architecture for recognition. Enzyme assays revealed that compound 50 caused a substancial increase in the Kmapp for ATP, while no significant effect was observed for derivative 54. This work also demonstrates the potential of the G5K enzyme as a biological target for the development of new anti-TB drugs G
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Selection of AmpC β-Lactamase variants and Metallo-β-Lactamases leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam resistance during treatment of MDR/XDR Pseudomonas aeruginosa infections

  • Ruedas-López, Alba
  • Alonso-García, Isaac
  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Gato, Eva
  • Vázquez-Ucha, Juan Carlos
  • Vallejo, J. A.
  • Fraile-Ribot, Pablo Arturo
  • Fernández-Pérez, Begoña
  • Velasco, David
  • Gutiérrez-Urbón, José María
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Bou, Germán
[Abstract] Infections caused by ceftolozane-tazobactam and ceftazidime-avibactam-resistant P. aeruginosa infections are an emerging concern. We aimed to analyze the underlying ceftolozane-tazobactam and ceftazidime-avibactam resistance mechanisms in all multidrug-resistant or extensively drug-resistant (MDR/XDR) P. aeruginosa isolates recovered during 1 year (2020) from patients with a documented P. aeruginosa infection. Fifteen isolates showing ceftolozane-tazobactam and ceftazidime-avibactam resistance were evaluated. Clinical conditions, previous positive cultures, and β-lactams received in the previous month were reviewed for each patient. MICs were determined by broth microdilution. Multilocus sequence types (MLSTs) and resistance mechanisms were determined using short- and long-read whole-genome sequencing (WGS). The impact of Pseudomonas-derived cephalosporinases (PDCs) on β-lactam resistance was demonstrated by cloning into an ampC-deficient PAO1 derivative (PAOΔC) and construction of 3D models. Genetic support of acquired β-lactamases was determined in silico from high-quality hybrid assemblies. In most cases, the isolates were recovered after treatment with ceftolozane-tazobactam or ceftazidime-avibactam. Seven isolates from different sequence types (STs) owed their β-lactam resistance to chromosomal mutations and all displayed specific substitutions in PDC: Phe121Leu and Gly222Ser, Pro154Leu, Ala201Thr, Gly214Arg, ΔGly203-Glu219, and Glu219Lys. In the other eight isolates, the ST175 clone was overrepresented (6 isolates) and associated with IMP-28 and IMP-13, whereas two ST1284 isolates produced VIM-2. The cloned PDCs conferred enhanced cephalosporin resistance. The 3D PDC models revealed rearrangements affecting residues involved in cephalosporin hydrolysis. Carbapenemases were chromosomal (VIM-2) or plasmid-borne (IMP-28, IMP-13) and associated with class-1 integrons located in Tn402-like transposition modules. Our findings highlighted that cephalosporin/β-lactamase inhibitors are potential selectors of MDR/XDR P. aeruginosa strains producing PDC variants or metallo-β-lactamases. Judicious use of these agents is encouraged., his work was supported by Projects and PI18/00501 to GB PI17/01482 and PI20/01212 awarded to AB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013 to 2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB and IN607D 2021/12 awarded to AB. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013 to 2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth from 2014 to 2020. CGB acknowledges the financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29) and Centro singular de investigación de Galicia accreditation from 2019 to 2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF). CLM was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN607A 2020/05 Grant (Xunta de Galicia). JCVU was financially supported by the pFIS program (ISCIII, PI17/01482). M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006). JAS was financially supported by the Rio Hortega program (ISCIII-SERGAS, CM19/00219).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification

  • Gato, Eva
  • Guijarro-Sánchez, Paula
  • Alonso-García, Isaac
  • Pedraza-Merino, Rosa
  • Conde, Adrián
  • Lence, Emilio
  • Rumbo-Feal, Soraya
  • Peña-Escolano, Andrea
  • Lasarte-Monterrubio, Cristina
  • Blanco Martín, Tania
  • Fernández González, Ana
  • Fernández-López, María del Carmen
  • Maceiras, Romina
  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Martínez-Martínez, Luis
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Objectives: In order to inform and anticipate potential strategies aimed at combating KPC-producing Klebsiella pneumoniae infections, we analysed imipenem/relebactam and ceftazidime/avibactam single-step mutant frequencies, resistance development trajectories, differentially selected resistance mechanisms and their associated fitness cost using four representative high-risk K. pneumoniae clones. Methods: Mutant frequencies and mutant preventive concentrations were determined using agar plates containing incremental concentrations of β-lactam/β-lactamase inhibitor. Resistance dynamics were determined through incubation for 7 days in 10 mL MH tubes containing incremental concentrations of each antibiotic combination up to their 64 × baseline MIC. Two colonies per strain from each experiment were characterized by antimicrobial susceptibility testing, whole genome sequencing and competitive growth assays (to determine in vitro fitness). KPC variants associated with imipenem/relebactam resistance were characterized by cloning and biochemical experiments, atomic models and molecular dynamics simulation studies. Results: Imipenem/relebactam prevented the emergence of single-step resistance mutants at lower concentrations than ceftazidime/avibactam. In three of the four strains evaluated, imipenem/relebactam resistance development emerged more rapidly, and in the ST512/KPC-3 clone reached higher levels compared to baseline MICs than for ceftazidime/avibactam. Lineages evolved in the presence of ceftazidime/avibactam showed KPC substitutions associated with high-level ceftazidime/avibactam resistance, increased imipenem/relebactam susceptibility and low fitness costs. Lineages that evolved in the presence of imipenem/relebactam showed OmpK36 disruption, KPC modifications (S106L, N132S, L167R) and strain-specific substitutions associated with imipenem/relebactam resistance and high fitness costs. Imipenem/relebactam-selected KPC derivatives demonstrated enhanced relebactam resistance through important changes affecting relebactam recognition and positioning. Conclusions: Our findings anticipate potential resistance mechanisms affecting imipenem/relebactam during treatment of KPC-producing K. pneumoniae infections., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support (to G.B.) and relebactam. This work was also supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 and PI21/00704 for G.B.) integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III (ISCIII), CIBERINFEC (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe.’ The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.). PGS was financially supported by IN606A-2021/021. I.A.-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/ 029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). Financial support from the Spanish Agency of Research (PID2019-105512RB-I00/AEI/10.13039/501100011033, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), CG-B], and the European Regional Development Fund (ERDF) is gratefully acknowledged. AC acknowledges Banco Santander for his fellowship. We are also grateful to the Centro de Supercomputación de Galicia (CESGA) for use of the Finis Terrae computer., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; IN606A-2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antimicrobial activity of Cefiderocol against the Carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with Metallo-β-Lactamase VIM-1

  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Álvarez-Fraga, Laura
  • Outeda-García, Michelle
  • Martínez Guitián, Marta
  • Peña-Escolano, Andrea
  • Maceira, Romina
  • Lence, Emilio
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Emergence of cefiderocol resistance among carbapenemase-producing Enterobacterales, particularly those in the Enterobacter cloacae complex (ECC), is becoming of alarming concern; however, the mechanistic basis of this phenomenon remains poorly understood. We describe the acquisition of VIM-1-mediated reduced cefiderocol susceptibility (MICs 0.5 to 4 mg/L) in a collection of 54 carbapenemase-producing isolates belonging to the ECC. MICs were determined by reference methodologies. Antimicrobial resistance genomic analysis was performed through hybrid WGS. The impact of VIM-1 production on cefiderocol resistance in the ECC background was examined at microbiological, molecular, biochemical, and atomic levels. Antimicrobial susceptibility testing yielded 83.3% susceptible isolates and MIC50/90 values of 1/4 mg/L. Decreased susceptibility to cefiderocol was mainly associated with isolates producing VIM-1, with cefiderocol MICs 2- to 4-fold higher than for isolates carrying other types of carbapenemases. E. cloacae and Escherichia coli VIM-1 transformants displayed significantly enhanced cefiderocol MICs. Biochemical assays with purified VIM-1 protein revealed low but detectable cefiderocol hydrolysis. Simulation studies revealed how cefiderocol is anchored to the VIM-1 active site. Additional molecular assays and WGS data analysis highlighted the implication of SHV-12 coproduction and suggested the inactivation of the FcuA-like siderophore receptor as further contributors to the higher cefiderocol MICs. Our findings warn of the potential of the VIM-1 carbapenemase to at least partly limit the activity of cefiderocol in the ECC. This effect is probably enhanced due to combination with additional mechanisms, such as ESBL production and siderophore inactivation, and indicates the need for active surveillance to extend the life span of this promising cephalosporin., This research was supported by Projects PI17/01482 and PI20/01212 awarded to AB, PI22/01212 to JAS and PI18/00501 to GB, within in the National Plan for Scientific Research, Development and Technological Innovation 2017 to 2020 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III). The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación-Consellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. It was also supported by Planes Nacionales de I+D+i2017 to 2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth2014 to 2020. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 Grant (Xunta de Galicia), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). M.O. was financially supported by IN607D 2021/12 (Xunta de Galicia). I.A.-G. was financially supported by the Rio Hortega program (ISCIII, CM21/00076). C.G.-B. acknowledges financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation2019 to 2022 [ED431G 2019/03]), and the European Regional Development Fund (ERDF)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Switching from ultrafast electron transfer to proton transfer in excited drug-protein complexes upon biotransformation

  • Tamarit, Lorena
  • El Ouardi, Meryem
  • Lence, Emilio
  • Andreu, Inmaculada
  • González-Bello, Concepción
  • Vayá, Ignacio
  • Miranda, M. A.
Photosensitization by drugs is directly related with the excited species and the photoinduced processes arising from interaction with UVA light. In this context, the ability of gefitinib (GFT), a tyrosine kinase inhibitor (TKI) used for the treatment of a variety of cancers, to induce phototoxicity and photooxidation of proteins has recently been demonstrated. In principle, photodamage can be generated not only by a given drug but also by its photoactive metabolites that maintain the relevant chromophore. In the present work, a complete study of O-desmorpholinopropyl gefitinib (GFT-MB) has been performed by means of fluorescence and ultrafast transient absorption spectroscopies, in addition to molecular dynamics (MD) simulations. The photobehavior of the GFT-MB metabolite in solution is similar to that of GFT. However, when the drug or its metabolite are in a constrained environment, i.e. within a protein, their behavior and the photoinduced processes that arise from their interaction with UVA light are completely different. For GFT in complex with human serum albumin (HSA), locally excited (LE) singlet states are mainly formed; these species undergo photoinduced electron transfer with Tyr and Trp. By contrast, since GFT-MB is a phenol, excited state proton transfer (ESPT) to form phenolate-like excited species might become an alternative deactivation pathway. As a matter of fact, the protein-bound metabolite exhibits higher fluorescence yields and longer emission wavelengths and lifetimes than GFT@HSA. Ultrafast transient absorption measurements support direct ESPT deprotonation of LE states (rather than ICT), to form phenolate-like species. This is explained by MD simulations, which reveal a close interaction between the phenolic OH group of GFT-MB and Val116 within site 3 (subdomain IB) of HSA. The reported findings are relevant to understand the photosensitizing properties of TKIs and the role of biotransformation in this type of adverse side effects., Financial support from the Spanish Ministry of Science and Innovation (RYC-2015-17737, BEAGAL 18/00211, PID2020-115010RB-I00/AEI/10.13039/501100011033, FPU19/00048, PID2019-105512RB-I00/AEI/10.13039/501100011033), the Xunta de Galicia (ED431C 2021/29), the Centro singular de investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputación de Galicia (CESGA) for use of the Finis Terrae computer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Singlet oxygen and radical-mediated mechanisms in the oxidative cellular damage photosensitized by the protease inhibitor simeprevir

  • García-Laínez, Guillermo
  • El Ouardi, Meryem
  • Moreno, Alejandro
  • Lence, Emilio
  • González-Bello, Concepción
  • Miranda, M. A.
  • Andreu, Inmaculada
Hepatitis C, a liver inflammation caused by the hepatitis C virus (HCV), is treated with antiviral drugs. In this context, simeprevir (SIM) is an NS3/4A protease inhibitor used in HCV genotypes 1 and 4. It is orally administered and achieves high virological cure rates. Among adverse reactions associated with SIM treatment, photosensitivity reactions have been reported. In the present work, it is clearly shown that SIM is markedly phototoxic, according to the in vitro NRU assay using BALB/c 3T3 mouse fibroblast. This result sheds light on the nature of the photosensitivity reactions induced by SIM in HCV patients, suggesting that porphyrin elevation in patients treated with SIM may not be the only mechanism responsible for SIM-associated photosensitivity. Moreover, lipid photoperoxidation and protein photooxidation assays, using human skin fibroblasts (FSK) and human serum albumin (HSA), respectively, reveal the capability of this drug to promote photodamage to cellular membranes. Also, DNA photo lesions induced by SIM are noticed through comet assay in FSK cells. Photochemical and photobiological studies on the mechanism of SIM-mediated photodamage to biomolecules indicate that the key transient species generated upon SIM irradiation is the triplet excited state. This species is efficiently quenched by oxygen giving rise to singlet oxygen, which is responsible for the oxidation of lipids and DNA (Type II mechanism). In the presence of HSA, the photobehavior is dominated by binding to site 3 of the protein, to give a stable SIM@HSA complex. Inside the complex, quenching of the triplet excited state is less efficient, which results in a longer triplet lifetime and in a decreased singlet oxygen formation. Hence, SIM-mediated photooxidation of the protein is better explained through a radical (Type I) mechanism., Financial support from the Spanish Ministry of Science and Innovation [PID2020-115010RB-I00/AEI/10.13039/501100011033 (I.A), PID2019-105512RB-I00/AEI/10.13039/501100011033 (CG-B) and FPU predoctoral fellowship for M. El O.], Axencia Galega de Innovaci´on (2020-PG067, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigaci´on de Galicia accreditation 2019–2022 (ED431G 2019/03),], and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputaci´on de Galicia (CESGA) for use of the Finis Terrae computer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Quinate-based ligands for irreversible inactivation of the bacterial virulence factor DHQ1 enzyme-A molecular insight

  • Rodríguez, Ángela
  • Maneiro, María
  • Lence, Emilio
  • Otero, José M
  • van Raaij, Mark J
  • Thompson, Paul
  • Hawkins, Alastair R
  • González-Bello, Concepción
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2023.1111598/ full#supplementary-material, Irreversible inhibition of the enzyme type I dehydroquinase (DHQ1), a promising target for anti-virulence drug development, has been explored by enhancing the electrophilicity of specific positions of the ligand towards covalent lysine modification. For ligand design, we made use of the advantages offered by the intrinsic acid-base properties of the amino substituents introduced in the quinate scaffold, namely compounds 6-7 (R configuration at C3), to generate a potential leaving group, as well as the recognition pattern of the enzyme. The reactivity of the C2-C3 bond (Re face) in the scaffold was also explored using compound 8. The results of the present study show that replacement of the C3 hydroxy group of (-)-quinic acid by a hydroxyamino substituent (compound 6) provides a time-dependent irreversible inhibitor, while compound 7, in which the latter functionality was substituted by an amino group, and the introduction of an oxirane ring at C2-C3 bond, compound 8, do not allow covalent modification of the enzyme. These outcomes were supported by resolution of the crystal structures of DHQ1 from Staphylococcus aureus (Sa-DHQ1) and Salmonella typhi (St-DHQ1) chemically modified by 6 at a resolution of 1.65 and 1.90 Å, respectively, and of St-DHQ1 in the complex with 8 (1.55 Å). The combination of these structural studies with extensive molecular dynamics simulation studies allowed us to understand the molecular basis of the type of inhibition observed. This study is a good example of the importance of achieving the correct geometry between the reactive center of the ligand (electrophile) and the enzyme nucleophile (lysine residue) to allow selective covalent modification. The outcomes obtained with the hydroxyamino derivative 6 also open up new possibilities in the design of irreversible inhibitors based on the use of amino substituents., Financial support from the Spanish State Agency of Research (PID2019-105512RB-I00/AEI/10.13039/501100011033, CG-B), the Xunta de Galicia (ED431C 2021/29 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/ 03), CG-B), and the European Regional Development Fund (ERDF) is gratefully acknowledged., Peer reviewed